Teams led by Bio21's Prof Michael Parker and Prof Karlheinz Peter, Baker in the new Department of Cardiometabolic Health are developing a new anti-inflammatory drug.
Bio21's Michael Parker is part of an international collaboration that has shown how the bacteria Gardnerella vaginalis targets cells and causes infection in women